Pfizer Inc PFE and BioNTech SE BNTX have announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the COVID-19 vaccine in children six months through 4 years of age.
FDA Emergency Use Authorization (EUA) for this age group was given in June. A conditional marketing application is under review by the European Medicines Agency.
Vaccine efficacy was 73.2% among children six months through 4 years of age without evidence of prior COVID-19 infection.
This analysis was based on 13 cases in the Pfizer-BioNTech COVID-19 Vaccine group (n=794) and 21 cases in the placebo group (n=351).
The observed cases were primarily caused by omicron BA.2. Omicron BA.4 and BA.5 strains were emerging during the study, with only a few cases accrued. Efficacy results against these strains were inconclusive.
The companies are working with the FDA to prepare a EUA application for an omicron BA.4/BA.5-adapted bivalent vaccine in children six months through 11 years of age.
Among children ages 6 through 23 months, the vaccine was 75.8% effective at preventing COVID-19 and 71.8% for children ages 2 through 4.
Three 3-µg doses of the shot continue to be well-tolerated in this age group.
Price Action: PFE shares are down 0.29% at $48.76, and BNTX stock is down 0.27% at $147.90 during the premarket session on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.